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Summary The serine protease urokinase plasminogen activator (uPA) is causally involved in cancer invasion and metastasis. Activity of this
protease in vivo is controlled principally by two inhibitors, one of which is plasminogen activator inhibitor type 2 (PAI-2). In this study, we show
that PAI-2 levels were significantly higher in primary breast carcinomas (n = 152) than benign breast tumours (n = 18). In the primary cancers,
PAI-2 levels correlated weakly but significantly with those of uPA and PAI-1, but not with tissue type plasminogen activator (tPA) or uPA
receptor (uPAR) levels. Using Northern blotting, mRNA for PAI-2 was&found in 28.6% of 49 primary breast cancers. In contrast to findings at
the protein level, PAI-2 mRNA levels failed to correlate with those for uPA or PAI-1. After immunocytochemistry with primary cancers, PAI-2
was detected predominantly in the malignant cells of primary carcinomas but was also present in stromal cells. Using the median value as a
cut-off point, PAI-2 showed no significant relationship with either disease-free interval or overall survival. However, using an optimum cut-off
value, patients with low levels of PAI-2 had a worse outcome than those with a high level. We conclude that, unlike PAI-1, high levels of
PAI-2 may be a favourable prognostic marker in breast cancer.
Keywords: plasminogen activator inhibitor 1; plasminogen inhibitor activator 2; urokinase plasminogen activator; tissue plasminogen
activator; immunochemistry; enzyme-linked immunosorbent assay; Northern blotting; breast cancer
Urokinase plasminogen activator (uPA) is a serine protease that is
causally involved in cancer invasion and metastasis (for review,
see Duffy, 1993). Consistent with its role in cancer spread, uPA
has been shown to be a prognostic marker in many different types
of human cancer (for review, see Duffy, 1996). As with most
proteases, activity of uPA is regulated in vivo by inhibitors. The
two best-characterized endogenous inhibitors of uPA are plas-
minogen activator inhibitor type 1 (PAI-1) and PAI-2. Both PAI-I
and PAI-2 belong to the serpin family of protease inhibitors
(Astedt et al, 1987; Andreasen et al, 1990). PAI-I is a 52-kDa
protein, whereas PAI-2 exists in two forms: a 60-kDa glycosylated
secreted form and a 47-kDa non-glycosylated form. Both PAI-I
and PAI-2 have been shown to inhibit extracellular matrix (ECM)
degradation in vitro (Baker et al, 1990; Cajot et al, 1990).
Furthermore, administration of a recombinant PAI-2 to mice
decreases tumour growth (Astedt etal, 1995), whereas overexpres-
sion of either PAI-I or PAI-2 results in inhibition of metastasis
(Mueller et al, 1995; Soff et al, 1995). These effects ofPAI-I and
PAI-2 are probably mediated through inhibition ofuPA activity.
Although PAI-I has been extensively studied in human cancers,
especially breast cancer (Gr0ndahl-Hansen et al, 1993; Janicke et
al, 1993; Reilly etal, 1992; Bianchi etal, 1995), less information is
available on PAI-2 levels in human malignancies (Bouchet et al,
1994; Foekens et al, 1995). The aim of this investigation was,
therefore, to study PAI-2 in different types of breast tumours and
to relate its levels to other components of the plasminogen acti-
vator system, to pathological characteristics of the tumours and,
finally, to patient outcome.
Received 15 November 1996
Revised 7February 1996
Accepted24 February 1996
Correspondence to: MJ Duffy
METHODS
Assay of uPA, uPA receptor, tPA, PAI-1 and PAI-2 by
enzyme-linked immunosorbent assay
uPA, uPA receptor (uPAR), tPA, PAI-I and PAI-2 were all assayed
as described previously (Duggan et al, 1995). Briefly, tumours
were homogenized in 50 mM Tris buffer (pH 7.4) containing 1 mM
monothiolglycerol. The homogenate was centrifuged at 2000 g for
10 min and the supematant extracted with 1% Triton X-100.
Centrifugation was then carried out at 10000 g for 20 min at
4°C. uPA, uPAR, PAI-1, PAI-2 and tPA were assayed on the super-
natant using enzyme-linked immunosorbent assay (ELISA) (kits
obtained from American Diagnostica, Greenwich, CT, USA). The
PAI-1 assay detects both latent and active forms of PAI-I as well
as PAI-I complexed to uPA. It does not react with PAI-2. The
PAI-2 ELISA detects both low and high molecular weight
forms of this inhibitor as well as uPA-PAI-2 complexes. This
assay is insensitive to PAI-1. The specificity ofthe uPA and uPAR
assays has been described previously (Duggan et al, 1995). The
tPA assay measures free tPA and tPA complexed to both PAI-I and
c2-antiplasmin. The main characteristics of the primary cancers
used for the ELISAs are summarized in Table 1. Of the 152
patients with primary breast cancer, follow-up information was
available on 148. Median patient follow-up was 5.50 years.
Adjuvant therapies administered are also listed in Table 1. Levels
of total protein were determined using the Bio-Rad Protein
Assay (Bio-Rad).
Assay of oestrogen receptor (ER) in breast tumours
Breast tumour cytosols were assayed for oestrogen receptors (ER)
using ELISA as described by Duffy et al (1986). The cut-offpoint
used was 200 fmol g-1 tissue.
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Detection of mRNA for uPA, uPAR, tPA, PAI-1 and PAI-2
by Northern blotting
Total RNA was extracted using guanidinium thiocyanate as
described by Chomczynski et al (1987). Integrity was checked on a
1% agarose gel, whereas concentration and purity were determined
by measuring the OD at 260 nm and 280 nm respectively. Before
electrophoresis, the RNA was denatured at 700C using 50% (v/v)
formamide and 16.6% (v/v) formaldehyde. Electrophoresis was
carried out on a 6-mm-thick 1% agarose-formaldehyde gel for 2-
3 h at 100 V. After separation under denaturing conditions, RNA
was transferred to Hybond-N membranes and the mRNA species of
interest located by hybridization with 32P-labelled cDNA probes.
mRNA band position was verified by measuring the distance
migrated with respect to a 0.24- to 9.5-kb RNA marker.
Preparation of oligonucleotide probes
Oligonucleotide probes were generated by polymerase chain
reaction (PCR) fronm a human placental cDNA library in kgtl1
(Clontech). The primer sequences used were as follows:
uPA
5'-GTCGTGGACTACATCGTCTACCTG
3'-CCATTCTCTTCCTTGGTGTGACTG
uPAR
5'-GCATTTCCTGTGGCTCATCAG
3'-GCGGAGTTACACGGTTGTACG
tPA
5'-GACTGGACGGAGTGTGAGCTCTCC
3'-GTAGTTGGTAACCTTGGTGTACAC
PAI-2
5'-CCTATGACAAACTCAACAAGTGG
3'-CTCCCTGTCATAACACCTCCTGTG
PAI-I
5'-GTGGTCTGTGTCACCGTATCTCAGG
3'-CATTGAAGTGAGTCACCAATGCGG
GAPDH
5'-GCTGGCGCTGAGTACGTCGTGGAG
3'-CTCTTCCTCTTGTGCTCTTGCTGG
The cDNA was heated to 96°C to denature the DNA before PCR.
The thermal cycles were: 1 min at 920C for denaturation, 2 min at
60°C for annealing ofprimers and 2 min at 72°C for polymeriza-
tion ofDNA, for a total of40 cycles. The sizes ofthe probes were
as follows: uPA, 564 bp; PAI-1, 356 bp; uPAR, 466 bp; PAI-2,
279 bp; tPA, 438 bp; and GAPDH 683 bp. Probes were labelled
with [a-32P]dCTP using arandomprimedlabelling kit(Boehringer
Mannheim).
Probe specificity was confirmedbycarrying outBLAST searches
against the EMBL database. Sequence homologies for each of the
probes corresponded to their target gene sequence. In addition, both
the hybridization and washing conditions were highly stringent (2 x
SSC, and 2 x SSC/0.1% SDS at 65°C respectively).
Semiquantitation of mRNAs
The radiolabelled blots were exposed to phosphor screens for 48 h
and analysed using a Molecular Dynamics Phosphor Imager 425,
and ImageQuant software. The band intensity ofuPA, PAI-1, PAI-
2, uPAR andtPA were expressed relative to thatofGAPDH, which
was used as the internal control.
Table 1 Age, nodal status, tumour size (pathological), ER status and
adjuvant treatment of patients with primary breast cancer
Number %
Age (years)
< 50 68 44.7
> 50 84 55.3
Tumour size (cm)
< 2.0 39 25.7
> 2.0,<5.0 61 40.1
>5.0 25 16.4
Unknown 27 17.8
No. axillary nodes with metastasis
Negative 62 40.8
Positive 63 41.4
Unknown 27 17.8
Oestrogen receptor status
Positive 87 57.2
Negative 57 37.5
Unknown 8 5.3
Adjuvant therapy
Tamoxifen 94 61.8
Chemotherapy 16 10.5
Tamoxifen and chemotherapy 6 3.9
Oophorectomy 1 0.7
No treatment 35 23.1
Immunocytochemistry
Five-micron cryostat sections were cut from 31 primary breast
cancers and dried overnight at room temperature. They were then
fixed in acetone at room temperature for 10 min and stored at
-70°C until use. Sections were allowed to thaw for 2 h at room
temperature before staining. Staining of PAI-2 was carried out
overnight at4'C with the monoclonal antibody HDPAI-2 22.1, at a
concentration of 8 ,ug ml-'. Visualization of the antigen was
performed using the standard avidin-biotin (ABC) procedure
(Vectastain Elite Murine ABC kit, Vector Laboratories,
Burlingame, CA, USA). All incubations were carried out as
recommended in the kit insert. Finally, the sections were counter-
stained using Harris's haematoxylin, dehydrated, cleared and
mounted in DPX. Full-term placenta was used as positive control,
whereas negative controls consisted of omission of the primary
antibody and the use ofan isotype control antibody.
Staining was semiquantitated using a four-level scoring system
as follows: level 1, no staining; level 2, 1-10% of cells positive;
level 3, 11-49% ofcells positive; and level 4, > 50% ofcells posi-
tive. Immunoreactivity oftumour and stromal cells were evaluated
separately.
Statistical analysis
The strength of associations between the various parameters
measured were tested using non-parametric tests. The
Kruskall-Wallis and Mann-Whitney tests were used for categor-
ical variables, and the Spearman rank correlation was used for
continuous variables. Survival analysis was carried out using
the log-rank test in association with Kaplan-Meier analysis.
Multivariate analysis was performed using the Cox proportional
hazard model. Optimum cut-offs were determined using the
maximal log-rank test, and confirmed using correlation and
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Table 2 Median and range of values for PAI-2, PAI-1, uPA, uPAR and tPA
proteins in benign breast tumours, primary breast carcinomas, and breast
cancer metastases
Tumour type n Median Range
ng mg-' protein
PAI-2 Benign 18 0.211 0-0.65
Primary 152 0.533 0-33.8
Metastases 17 0.627 0-4.73
PAI-1 Benign 18 0.372 0-4.33
Primary 152 0.710 0-26.60
Metastases 17 0.696 0.028-29.5
uPA Benign 18 0.052 0-0.727
Primary 152 0.376 0-10.2
Metastases 17 0.244 0-2.39
uPAR Benign 16 0.097 0-0.28
Primary 115 0.207 0-2.27
Metastases 14 0.118 0-0.30
tPA Benign 18 2.312 0.410-8.23
Primary 152 1.550 0-53.2
Metastases 17 0.870 0-3.90
regression tree analysis (CART). All tests were two-sided and
P-values below 0.05 were considered statistically significant.
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Figure 1 Relationship between PAI-1 and PAI-2 in primary breast tumours.
The statistical test used was the Spearman coefficient of rank correlation.
n= 152; r= 0.175; P= 0.0315
RESULTS
Distribution of PAI-2 in different types of breast
tumours
Table 2 shows the median and range ofvalues for PAI-2 in benign
breast tumours (fibroadenomas), primary breast cancer and
metastatic breast cancers (axillary node metastases). Levels of
PAI-2 were significantly higher in the primary carcinomas than
in the benign tumours (P = 0.0006, Mann-Whitney U-test).
However, levels were not significantly different in primary carci-
nomas and nodal metastases. In the primary cancers, PAI-2 levels
showed no significant relationship with either tumour size, nodal
status or ER status.
Relationship between PAI-2 protein levels and other
parameters of the PA system
The median and range of values for PAI-2, uPA, PAI-1, uPAR and
tPA are summarized in Table 2. PAI-2 levels correlated weakly but
significantly with both PAI-I (r = 0.175, P = 0.0315, n = 152) and
uPA levels (r = 0.212, P = 0.0092, n = 152) (Figures 1 and 2). In
contrast, PAI-2 showed no significant relationship with either tPA
or uPAR levels.
Detection of mRNA for PAI-2 using Northern blotting
Figure 3 shows typical Northern blots for PAI-2 mRNA.
Transcripts for this species were detected in 14 out of49 (28.6%)
of the primary cancers. Transcripts for uPA were found in 75.6%
of samples: PAI-1, 28.6%; uPAR, 57.1%; and tPA, 30.6%. No
significant correlation was found between PAI-2 mRNA levels and
those for PAI-1, uPA, uPAR and tPA. In contrast to PAI-2, PAI-I
mRNA levels were significantly related to those ofuPA (r = 0.318,
P = 0.0391, n = 43).
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Figure 2 Relationship between uPA and PAI-2 in primary breast tumours.
The statistical test used was the Spearman coefficient of rank correlation.
n= 152; r=0.212; P=0.0092
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Immunocytochemical localization of PAI-2
Using the monoclonal antibody HDPAI-2 22.1, cytoplasmic and
membrane staining for PAI-2 was found in both malignant and
stromal cells. However, immunostaining was detected predomi-
nantly in malignant cells (Figure 4). The staining scores for these
two cell types are summarized in Table 3. Staining for both cell
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Figure 3 Typical Northern blots for PAI-2 from primary breast cancers
Table 3 Epithelial and stromal staining scores for PAI-2 in 31 primary breast
cancer samples. The scoring system is described in Methods
Staining score Epithelial cells Stromal cells
n (%) n (%)
3 10 (32.25) 5 (16.13)
2 7 (22.58) 7 (22.58)
1 8 (25.82) 13 (41.94)
0 6 (19.35) 6 (19.35)
types (i.e. greater than level 1) was found in 25 out of 31 (80.6%)
oftumours. However, there was no significant correlation between
the immunocytochemistry scores in the respective cell types. As
with PAI-2 levels detected by ELISA, there was no significant
correlation between immunocytochemistry scores for PAI-2 and
tumour size, nodal status or ER status.
Relationship between PAI-2 levels and patient
prognosis
Using the median value ofthe primary cancers (i.e. 0.533 ng mg-'
protein) as cut-off point, no significant relationship was found
between PAI-2 levels, as detected by ELISA and patient outcome.
However, using an optimum cut-off point of 0.1 ng mg-' protein,
patients with low levels ofthe inhibitor had both a shorter disease-
free interval [Figure SA; chi-square = 4.25, relative risk (RR) =
1.91, P = 0.0392] and overall survival (Figure SB chi-square =
6.45, RR = 2.19, P = 0.021) than patients with high levels. It
should be pointed out that this optimum cut-off point for PAI-2
was at the 12.5 percentile level.
Table 4 Comparative prognostic value of PAI-2, uPA, PAI-1 and tPA in breast cancer using both univariate and multivariate analysis.
Variable n Disease-free interval Overall survival
High/Iowa
Univariate Multivariate Relative Univariate Multivariate Relative
P P risk P P risk
PAI-2 128/20 0.0392 0.0035 0.373 0.0111 0.0001 0.329
uPA 41/107 < 0.0001 0.0001 2.400 0.0002 0.0027 2.454
PAI-1 71/77 0.0032 0.0046 2.169 0.0022 0.0013 2.614
tPA 86/62 0.0134 0.0250 0.556 0.0069 0.0074 0.466
The optimum cut-off points were as follows: PAI-2, 0.1 ng mg-' protein; uPA, 0.81 ng mg-' protein; PAI-1, 0.74 ng mg-' protein and tPA, 1.31 ng mg-' protein. For
each parameter, high values were compared with low values. aHigh/low refers to the numbers of each of the proteins above and below the cut-off point
respectively.
Figue4 mmuncytohemitryfPA-2inbreast e. P s
Figure 4 Immunocytochemistry of PAI-2 in breast cancer. Photograph shows malignant cell staining for PAI-2. Bar, 30 mm
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Table 5 Prognostic value of PAI-2 in different subgroups of patients with
breast cancer
Subgroup n Disease-free Overall survival
interval
x2 p x2 P
Axillary node negative 62 NS NS
Axillary node positive 63 6.77 0.0093 6.51 0.0107
ER negativea 56 7.28 0.0070 9.26 0.0026
ER positivea 86 NS NS
Tumour size < 2 cm 39 NS NS
Tumour size > 2 cm 86 NS NS
uPAlow 107 NS NS
uPA high 41 7.42 0.0064 9.67 0.0019
The cut-off point used for PAI-2 was 0.1 ng mg-' protein. Results are based
on univariate analysis and the log-rank test. aThe differences in the number
of patients who are ER positive and negative in this table, compared with
Table 1, are due to 2 patients on whom follow-up data were unavailable.
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Table 4 compares the prognostic value ofPAI-2 with uPA, PAI- I
and tPA. Using univariate analysis, the prognostic impact ofPAI-2
was less strong than the other three parameters. However, in multi-
variate analysis, PAI-2 as a prognostic marker was independent of
uPA, PAI-I and tPA. Similarly, uPA, PAI- I and tPA were indepen-
dent prognostic factors. uPAR was not included in this comparative
study, as results for this component were only available on 115
primary cancers. Finally, PAI-2 was investigated for possible prog-
nostic value in different subgroups of patients with breast cancer
(Table 5). Using the optimum cut-off point, PAI-2 levels were
significantly related to outcome in the following subgroups: node-
positive, ER-negative and patients with high levels of uPA (i.e.
> 0.81 ng mg-' protein, which was the optimum cut-off point for
discriminating between patients with good and poor outcome).
DISCUSSION
Although PAI-I has been widely studied in different human
cancers, much less information is available on PAI-2. As with PAI-
1 (Reilly et al, 1992), we show here that PAI-2 protein levels are
also significantly correlated with those for uPA in breast cancer.
However, the relationship between PAI-2 and uPA is less strong
than that between PAI-I and uPA. PAI-2 concentrations correlated
weakly but significantly with those for PAI-I levels at the protein
but not at the mRNA level. Similar correlations between levels of
PAI-2 protein and both uPA and PAI-1 have been reported by
others (Foucre et al, 1991; Foekens et al, 1995). The lack of corre-
lation at the mRNA level may be due to the smaller number of
samples used for Northern blotting than for ELISA.
Using immunocytochemistry, we show that PAI-2 protein is
found principally in malignant cells but is also present in stromal
cells. Relatively little work appears to have been published on the
detection of PAI-2 by immunocytochemistry in breast cancer.
Using unprocessed tissue we previously found, using both mono-
clonal and polyclonal antibodies, that PAI-i was mostly confined
to tumourcells in breast cancer (Reilly et al, 1992). However, using
paraffin-embedded tissue Bianchi et al (1995) found that PAI-i
was predominantly located in stromal cells, although epithelial cell
staining was also present. In colon cancer, PAI-I mRNA was found
principally in endothelial cells. In this malignancy, no mRNA for
PAI-I was detected in the cancer cells (Pyke et al, 1991).
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Figure 5 A Relationship between PAI-2 levels and disease free interval
using an optimum cut-off point of 0.1 ng mg-' protein. Differences in outcome
were determined using the log-rank test, and the optimum cut-off point was
calculated using the maximal log-rank test. There were eight (40%) relapses
in the low PAI-2 group compared with 35 (27.34%) in the high PAI-2 group.
Chi-square = 4.25; P= 0.0392; RR = 1.91. B Relationship between PAI-2
levels and overall survival using an optimum cut-off point of 0.1 ng mg-'
protein. Differences in outcome were determined using the log-rank test, and
the optimum cut-off point was calculated using the maximal log-rank test.
Chi-square = 6.45; P= 0.0211; RR = 2.19
Our median levels for PAI-2 protein are lower than those previ-
ously reported (Foucre etal, 1991; Sumiyoshi et al, 1992; Foekens et
al, 1995). These differences are probably related to the different
assays used, i.e. different standards and different antibodies. How-
ever, our median values for PAI-2, PAI-1, uPA and uPAR are very
similar to those previously reported by us (Duggan et al, 1995). In
agreement with other investigators, we found no significant relation-
shipbetweenPAI-2proteinlevels andestablishedprognostic markers
for breast cancer such as tumour size, nodal status and ER status
(Foucre et al, 1991). Using the median value as a cut-off point,
Foekens et al (1995) found no significant relationship between PAI-2
levels andeitherlymphnode status orERstatus,butdidfindthatPAI-
2 levels were significantly higher in smaller than larger tumours. In
contrast to thesefindings, Sumiyoshi et al (1992) reported that PAI-2
levels werehigher in carcinomas without than with nodal metastases.
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The pathophysiological significance of the presence of both
PAI-I and PAI-2 in cancer is unclear. As one of the functions of
these molecules is to inhibit uPA, it might be expected that high
levels of these inhibitors would minimize cancer invasion and
metastasis. In model systems, both PAI-I and PAI-2 have indeed
been shown to do this (see Introduction). However, in human
breast cancer, high levels of PAI-I are associated with poor prog-
nosis (Gr0ndahl-Hansen et al, 1993; Janicke et al, 1993; Foekens
et al, 1994). These findings suggest that PAI-i plays a role in the
spread of cancer, perhaps by protecting the tumour from proteo-
lysis during metastasis (Reilly et al, 1992).
Unlike PAI-1, high levels of PAI-2 do not appear to be associ-
ated with aggressive disease in breast cancer. Using an optimum
cut-off point (i.e. 14.5 ng mg-' protein) Bouchet et al (1994)
reported that high levels of PAI-2 were associated with both a
longer disease-free interval and metastasis-free survival. In this
study, however, only 14% ofpatients had high levels of PAI-2. In
our study using an optimum cut-off of 0.1 ng mg-' protein, only
12.5% of patients had a low level of PAI-2. Foekens et al (1995)
found no relationship between PAI-2 levels andpatient outcome in
the overall population. However, in patients with high levels of
uPA, increasing PAI-2 levels were associated with improved prog-
nosis. In this investigation we also show thatPAI-2 levels correlate
with outcome in patients with high uPA levels. However, we also
show thatPAI-2 is prognostic in othersubgroups ofpatients gener-
ally associated with aggressive disease, i.e. node-positive and ER-
negative patients. Our results with uPA, PAI-I and tPA, reported
here, are in agreement with published data. Many different groups
have shown that both uPA (for review see Duffy, 1996) and PAI-I
(see above) are strong and independent prognostic factors in breast
cancer. Using an immunoradiometric assay (IRMA), we have
reported previously that high levels of tPA predicted improved
outcome in patients with breast cancer (Duffy et al, 1988). It
should be pointed out, however, that the optimum cut-off point
found for tPA using the present ELISA is lower than that previ-
ously obtained using IRMA. Again, the differences will probably
relate to different standards and antibodies used in the ELISA and
IRMA. The optimum cut-off point found for uPA in the present
study was identical to that used in the previous study using the
American Diagnostica ELISA (Duggan et al, 1995).
We conclude that high PAI-2 levels, unlike those for PAI-1, are
not associated with aggressive disease. On the other hand, high
levels of PAI-2 may correlate with good prognosis, at least in
certain subgroups of patients. These findings suggest that PAI-2
may be a favourable prognostic marker in breast cancer.
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